Neoadjuvant chemotherapy prior to radical cystectomy for muscle ‐invasive bladder cancer with variant histology

CONCLUSIONSPatients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better overall survival and lower rates of non‐organ‐confined disease at the time of RC. For tumors with micropapillary differentiation, sarcomatoid differentiation, or adenocarcinoma, neoadjuvant chemotherapy decreased the frequency of non‐organ‐confined disease at the time of RC. However, this favorable effect did not translate into a statistically significant overall survival benefit for these patients, potentially due to the aggressive tumor biology. Cancer 2017;000:000‐000. © 2017 American Cancer Society. (Source: Cancer)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uWaMyH
via IFTTT